dr. Agata Zamborlin (PhD)

CRIG member
Agata Zamborlin


Postdoctoral researcher - Lab of General Biochemistry and Physical Pharmacy, Ghent Research Group on Nanomedicines - Faculty of Pharmaceutical Sciences (UGent)
Principal investigator: Prof. Koen Raemdonck (PhD) 
 

Research focus

New strategies for RNA delivery to the lung, with applications in chronic inflammatory diseases and lung cancer.
 

Biography

MSc in Pharmaceutical Chemistry and Technology at University of Padua (Italy), she developed her interest in drug delivery with a master thesis about targeted gold nanoparticles for delivery and controlled release of anticancer drugs. She pursed a Ph.D. in Nanoscience at Scuola Normale Superiore in Pisa and Italian Institute of Technology (Italy) under the supervision of Dr. Valerio Voliani working on hybrid nanomaterials for metastasis modulation. During her PhD, she developed non-invasive cancer treatments based on plasmonic nanotherapeutics, with a special focus on antimetastatic agents. She is currently a postdoctoral fellow at Gent University under the supervision of Prof. Koen Raemdonck. Here, she is investigating new strategies for RNA delivery to the lungs, with applications in chronic inflammatory diseases and lung cancer.
 

Key publications

  • ‘Drug-Free Hybrid Nanoarchitecture Modulation of the Metastatic Behavior of Pancreatic Ductal Adenocarcinoma in Alternative in Vivo Models’. ACS Appl. Nano Mater., 2016
  • ‘Hyperthermia Reduces Irradiation-Induced Tumor Repopulation in an In Vivo Pancreatic Carcinoma Model’. Adv Biol (Weinh), 2023. (PMID: 36861331)
  • ‘Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma’. Cancers (Basel), 2022. (PMID: 35740699)
  • ‘Pro-apoptotic and size-reducing effects of protein corona-modulating nano-architectures enclosing platinum prodrug in in vivo oral carcinoma’. Biomater Sci., 2022. (PMID: 36069269)
  • ‘Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas’. J Mater Chem B., 2023. (PMID: 36484416)
  • ‘A bioconvergence study on platinum-free concurrent chemoradiotherapy for the treatment of HPV-negative head and neck carcinoma’. Artif Cells Nanomed Biotechnol., 2024. (PMID: 38315518)
  • ‘Organic Selenium induces ferroptosis in pancreatic cancer cells’. Redox Biol, 2023. (PMID: 38029455)
  • ‘Gold nanoparticles as antiangiogenic and antimetastatic agents’. Drug Discov Today, 2023 (PMID: 36375738)
  • ‘Evolving approaches in glioma treatment: harnessing the potential of copper metabolism modulation’. RSC Adv, 2023. (PMID: 38020008)
     

Contact & links